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Percutaneous intervention for infrainguinal
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John Karwowski, MD, Niren Angle, MD, Peter L. Faries, MD, and K. Craig Kent, MD,
New York, NY
Objectives: Experience with open surgical bypass suggests similar overall outcomes in women compared with men, but
significantly increased risk of wound complications. Percutaneous treatment of lower extremity occlusive disease is
therefore an attractive alternative in women, although it is not clear whether there is a difference in outcomes between
women and men treated with this technique. We sought to determine the results and predictors of failure in women
treated by percutaneous intervention.
Methods: Percutaneous infrainguinal revascularization was performed on 309 women between 2001 and 2006. Proce-
dures, complications, demographics, comorbidities, and follow-up data were entered into a prospective database for
review. Patency was assessed primarily by duplex ultrasonography. Outcomes were expressed by Kaplan-Meier curves and
compared by log-rank analysis.
Results: A total of 447 percutaneous interventions performed in 309 women were analyzed and compared with 553
interventions in men. Mean age in women was 73.2 years; comorbidities included hypertension (HTN) (86%), diabetes
melitus (DM) (58%), chronic renal insufficiency (CRI) (15%), hemodialysis (7%), hypercholesterolemia (52%), coronary
artery disease (CAD) (42%), and tobacco use (47%). Indications in women included claudication (38.0%), rest pain
(18.8%), and tissue loss (43.2%). Overall primary & secondary patency and limb-salvage rates for women were 38%  4%,
66%  3%, and 80%  4% at 24 months. In this patient sample, women were significantly more likely than men to present
with limb-threatening ischemia (61.6% vs 47.3%, P < 0.001) and have lesions of TASC C and D severity (71.4% vs 61.7%,
P < .005). However, there were no significant differences in primary and secondary patency rates or limb-salvage rates
between genders. Furthermore, while women with limb-threat, diabetes, and advanced TASC severity lesions were at
increased risk of failure overall, there were no differences between women and men with these characteristics.
Conclusions: Percutaneous infrainguinal revascularization is a very effective modality in women with lower extremity
occlusive disease. Although women in this sample were more likely to present with limb-threat than men, patency and
limb-salvage rates were equivalent between genders, even in high-risk subsets such as diabetics or those with lesions of
increased TASC severity. ( J Vasc Surg 2008;48:150-8.)Chronic lower extremity ischemia is a common mani-
festation of vascular disease that affects approximately 27
million persons in the United States and Western Europe
and is associated with up to a 15-fold increase in mortality
compared with those without evidence of peripheral vascu-
lar disease.1-3 In many centers, the mainstay of therapy for
chronic lower extremity ischemia has moved away from
surgical bypass and toward less invasive endovascular treat-
ment as a first line modality. As experience with endovas-
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150cular techniques has grown, percutaneous intervention has
been extended beyond the iliac circulation and into the
infrainguinal locations. Furthermore, the factors which
portend poor outcome after percutaneous intervention
have begun to become more clearly defined.4-8
The effect of gender differences on outcome following
percutaneous intervention is one area that remains to be
further elucidated. Prior studies have documented the neg-
ative correlation between female gender and outcome fol-
lowing cardiac interventions, including both open surgical
coronary revascularization and percutaneous transluminal
interventions.9-10 Substantial data has accumulated on the
relationship between gender and peripheral vascular disease
as well. There are numerous studies, for example, compar-
ing the outcome following lower extremity bypass in men
and women.11-17 While these reports are at times conflict-
ing, there appears to be a general consensus that men and
women have similar patency and limb-salvage rates after
open surgical bypass, and the primary difference between
genders is an increased risk of wound complications in
women.18-19 The lower wound complication rate associ-
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sive disease could reduce the frequency of these problems in
women, although less data is available on endovascular
therapy. There have been several publications pertaining to
gender differences after endovascular treatment of the iliac
circulation, and in these small series, female gender has
been associated with reduced intermediate and long-term
patency.20-21
Although infrainguinal interventions for lower extrem-
ity disease are becoming more commonly utilized, less has
been reported regarding outcomes for interventions at
these locations compared with the iliac circulation. In par-
ticular, gender differences and the effects of hormonal
replacement therapy on infrainguinal interventions are
largely unknown.
METHODS
Patients. Between the years 2001 and 2006, 309
women underwent 447 percutaneous interventions for in-
frainguinal lower extremity occlusive disease. These inter-
ventions were recorded in a prospectively maintained data-
base and compared with interventions performed on 421
male patients over the same time period. All patients re-
quired intervention for chronic lower extremity ischemia
and any patient requiring urgent or emergent intervention
(open or percutaneous) for acute ischemia was excluded
from analysis. This group of patients includes only those
with isolated infrainguinal interventions, and patients un-
dergoing simultaneous iliac interventions were excluded
from analysis. Indications included debilitating claudica-
tion (defined as severely impairing lifestyle and ranging
from 0.5 to 4 blocks) or limb-threatening ischemia (de-
fined as rest pain, tissue loss or ulceration).
Demographic information, comorbidities, presence of
hormone replacement therapy, operative details, and peri-
operative adverse events were determined by review of
patient charts, operative reports and pre- and postoperative
studies. Operative reports and angiograms were reviewed
to determine lesion TransAtlantic InterSociety Consensus
[TASC I] classification and location (femoral, popliteal, or
tibial).22 Postoperatively, patients were followed by physi-
cal exam and vascular lab evaluation. The divisional vascular
lab database was reviewed to determine the results of pre-
and postoperative noninvasive flow studies.
Procedures and imaging. Percutaneous interven-
tions included angioplasty with or without stent placement,
cryoplasty, and excisional atherectomy through either an
antegrade or retrograde femoral artery access under local
anesthesia with intravenous sedation. Procedures were per-
formed either in an angio-equipped operating room using
fixed fluoroscopic equipment (Siemens, Munich, Ger-
many) or with a portable imaging fluoroscopic C-arm
(OEC 9800; GE Medical Systems, Milwaukee, Wis). Io-
dinated contrast was used in patients with normal creati-
nine, and gadolium or combination gadolinium plus iodin-
ated contrast was used in most patients with creatinine level
greater that 1.3 mg/dl (use of gadolinium was determined
by surgeon preference, and the majority of these cases wereperformed prior to the “black-box” warning regarding the
potential link between gadolinium usage and nephrogenic
fibrosing dermopathy [NFD]). All procedures were per-
formed by members of the Division of Vascular Surgery,
and type of procedure utilized was left to the discretion of
the operating surgeon.
Technique. Selective angiography was performed to
localize lesions and allow planning of interventions. Short
5-8F sheaths were used for antegrade punctures, and 6-8F
Balkin sheaths (Cook, Bloomington, Ind) were used for
retrograde punctures and contralateral interventions. Pa-
tients were systemically anticoagulated with intravenous
heparin (100 units/kg) after sheath placement or before
crossing critical lesions. Activating clotting time was main-
tained above 250 seconds for femoropopliteal procedures
and above 300 seconds for tibial interventions. Lesions
were crossed with either a luminal or subintimal technique
using hydrophilic guide wires (0.035, 0.018, or 0.014
inch). Wires were supported using 4F or 5F angled glide
catheters (Angiodynamics, Queensbury, NY) or Quick
Cross catheters (Spectranetics, Colorado Springs, Colo).
Re-entry into the luminal space beyond the lesion was
confirmed by angiography before further intervention, and
rarely were re-entry devices utilized. Balloon angioplasty
was performed with appropriately sized noncompliant bal-
loons with inflation times ranging from 60 to 180 seconds
at 6 to 15 ATM of pressure. Stenting was performed
selectively for 30% residual stenosis or flow limiting dis-
sections. Excisional atherectomy was used as an alternative
to balloon angioplasty in 292 (18.1%) of treated vessel
locations, most commonly in the popliteal and tibial circu-
lation. The Silverhawk atherectomy device (Fox Hollow
Industries, Redwood City, Calif), which requires an 0.014
inch wire system, was used for all atherectomies. Pre- or
postatherectomy adjunctive procedures including angio-
plasty or angioplasty/stenting were required in 40.9% of
cases either to allow initial passage of the atherectomy
device or to treat residual disease following atherectomy.
Completion angiography with evaluation of the distal run-
off was performed following interventions.
Aspirin was administered to all patients postoperatively
unless contraindicated. For patients undergoing stent
placement or atherectomy, a loading dose of Plavix 450 mg
was administered in the post anaesthesia care unit, followed
by 75 mg/day for 30 days.
Endpoints. Patency was determined by arterial duplex
of the treated vessel and by ankle-brachial indices (ABI).
Loss of patency was defined as occlusion or a velocity ratio
of greater than 2.5:1 (representing a greater than 50%
reduction in the lumen diameter) on arterial duplex or as a
diminishment of0.15 in the ABI. Routine follow-up was
performed at 2 weeks postoperatively then at 6-month
intervals, and included physical examination (pulses,
wound healing, presence or absence of claudication or rest
pain) and vascular lab assessment (ankle-brachial indices
and arterial duplex ultrasound).
Statistical analysis. Demographic and comorbidity
data was reported as mean  standard deviation or as a
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while all treatment information, complications, patency
rates, and other outcomes were reported by intervention.
Univariate analysis of dichotomous variables between sub-
groups was performed by Fisher exact t test. Primary and
secondary patency and limb salvage rates were assessed
using Kaplan-Meier survival curves, and subgroups were
compared by log-rank analysis to determine factors predic-
tive of treatment failure. Multivariable analysis using
Cox-PH modeling was performed to assess factors that
were significant on univariate analysis.
RESULTS
Patients. Between 2001 and 2006, a total of 447
percutaneous lower extremity interventions were per-
formed in 309 women, compared with 553 interventions
performed in 421 men. Demographics and comorbidities
of all patients stratified by gender are listed in Table I.
Female patients were significantly older than the male
patients (73 vs 70 years, P  .0002). The most common
comorbidities for both men and women included hyper-
tension, hypercholesterolemia, diabetes, coronary artery
disease (CAD), and tobacco use. Chronic renal insuffi-
ciency (CRI), CAD, history of myocardial infarction (MI),
andhistory of tobaccousewere all significantlymore common
in men than women (P .001 for each, see Table I.)
Indications and lesion distribution. For all proce-
dures performed in women, 83.0% (371 interventions)
were primary interventions, while the remaining 17.0% (76
interventions) were performed as secondary procedures on
the same limb following re-stenosis or occlusion of the
primary treatment site. Reintervention was less likely in
men, who had 68 reinterventions and 485 primary inter-
ventions (P  .04), for an overall reintervention rate of
12.3%. Claudication was the indication in 38.0% of primary
interventions in women, and in the remaining 62.0% the
indication was limb-threatening ischemia. Women with
limb-threat were further divided into those who underwent
Table I. Demographics and comorbidities in men and
women undergoing percutaneous infra-inguinal intervention
Women
N (%)
Men
N (%) P value
Total 309 421
Age (y) 73.2 70.3 P  .001
Diabetes 177 (57.3%) 245 (58.2%) ns
Chronic renal
insufficiency 46 (14.9%) 114 (27.0%) P  .001
End stage renal
disease (HD) 21 (6.8%) 42 (10.0%) ns
Hypertension 264 (85.4%) 352 (83.6%) ns
Hypercholesterolemia 158 (51.1%) 263 (62.5%) ns
Prior CABG 45 (14.6%) 119 (28.2%) P  .001
Coronary artery
disease 129 (41.7%) 245 (58.2%) P  .001
History of MI 64 (20.7%) 134 (31.8%) P  .001
Tobacco use 144 (46.6%) 238 (56.5%) P  .001intervention for rest pain (30.4%) and those with gangreneor tissue loss (69.9%). In contrast, male patients underwent
intervention for claudication in 52.7% of primary interven-
tions, and presented with limb-threat to a lesser degree
than the women (47.3% for men vs 62.0% for women, P
.0001, see Table II). In addition to presenting with limb-
threatening ischemia more often, women were also more
likely to have advanced TASC classification lesions. In this
series, there was a preponderance of TASC B through D
lesions and few TASCA lesions (5.8% overall) in either men
or women.Womenwere significantly more likely to present
with TASC C and D lesions than men (71.4% vs 61.7%,
respectively, P  .005, see Table II). Reduced tibial out-
flow (3 vessel tibial outflow) was also common, existing
in 83.8% of women and 80.2% of men (P  0.05, ns).
Intervention was performed in the tibial location in 35.3%
of women and in the femoropopliteal location in 64.7%.
This treatment location distribution did not significantly
vary between men and women. There were a total of 755
distinct lesions treated in women and 857 lesions in men.
As displayed in Table III, the distribution of treated lesions
and the use of different treatment modalities were similar
between men and women. There was a trend toward in-
creased use of angioplasty alone vs angioplasty with stent-
ing in women compared with men, but this was not statis-
tically significant (P  .067).
Outcomes. Thirty-day perioperative mortality was
0.5% overall and similar for women and men (0.7% and
0.4%, respectively, P  .05). Complication rates were
equivalent between women and men, and included groin
hematoma in 5.0% (requiring operative exploration in
0.8%), and pseudoaneurysm formation in 3.4% (all treated
by thrombin injection) of all interventions. Renal dys-
function (increase in postoperative Cr by  0.5 mg/dl)
occurred in 2.0%, resulting in the need for hemodialysis
in 0.3%.
Mean andmedian follow-up for all patients was 8.7 and
5.0 months, respectively. Primary and secondary patency
rates (for all interventions) and limb-salvage rates (for
Table II. Presentation and lesion distribution/Severity
in primary interventions in men and women
Women
(n  371)
Men
(n  486) P value
Presentation
Claudication 141 (38%) 255 (52.0%) P  .0001
Limb-threat 230 (62%) 231 (47.3%)
- Rest pain 70 (18.9%) 51 (10.5%)
- Tissue loss 160 (43.1%) 180 (37.0%)
TASC classificationa
TASC A & B 106 (28.6%) 186 (38.3%) P  .005b
TASC C & D 265 (71.4%) 300 (61.7%)
Most distal
intervention
Femoropoliteal 240 (64.7%) 327 (67.3%) P  .05, ns
Tibial 131 (35.3%) 157 (32.3%)
aFor femoropopliteal lesions.
bFor TASC A/B vs C/D.patients with limb-threat) for men and women are illus-
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analysis (Figs 1, 2, and 3). For women, primary patency
rates at 12 and 24 months were 54%  3% and 39%  5%,
respectively, while secondary patency rates were signifi-
cantly higher at 75%  4% and 66%  4% (P  .001).
Limb-salvage rates (in women with limb-threatening con-
ditions) were 81%  3% and 80  4%. Twelve- and 24-
month primary patency rates for men were 59  3% and
45%  5%, respectively, while secondary rates were 77% 
3% and 66%  4%, respectively. Limb-salvage rates in men
were 82%  3% and 74%  5% at 12 and 24 months. As
shown in Figs 1, 2, and 3, there were no significant differ-
ences between primary and secondary patency or limb-
salvage rates between men and women, despite the higher
incidence of several important comorbidities in men.
Univariate log-rank analysis identified several factors
associated with reduced primary patency in women under-
Fig 1. Primary patency rate for all interventions in women and
men by Kaplan-Meier analysis. Women had 12- and 24-month
primary patency rates of 54% 3% and 40% 4%, respectively, and
primary patency did not vary for women and men.
Table III. Lesion distribution and treatment modality
utilization
Women Men P value
Lesion location P  .05, ns
Femoral 44% 46%
Popliteal 35% 34%
Tibial 22% 20%
Treatment modality P  .05, ns
Angioplasty alone 43% 39%
Angioplasty with stenting 37% 41%
Atherectomy 20% 20%going percutaneous lower extremity revascularization (seeFig 4, A and B). These included limb-threat as the present-
ing symptom or indication for intervention, lesions of
TASC C & D severity, diabetes, and reduced tibial vessel
runoff (3 vessel). Limb-threat as the presenting symptom
was the factor most strongly associated with reduced pa-
tency. Women undergoing percutaneous intervention who
presented with limb-threat had a 1-year primary patency of
42%  3%, compared with women with claudication who
had a patency rate of 67%  5%. Multivariate analysis
confirmed that limb-threat as the indication for interven-
tion (P  .0001), diabetes (P  .03), increasing TASC
severity (P .05), and reduced tibial runoff (P .05) were
each independently associated with reduced primary pa-
tency for both women and men. We found no significant
differences in primary and secondary patency or limb-
salvage for women compared with men when outcomes
were stratified by the risk factors identified on multivariate
analysis as well as all other proposed risk factors (see Fig 5,
A, B, and C).
There were no significant differences in patency or
limb-salvage between different treatment modalities (an-
gioplasty alone, angioplasty with stenting, or atherectomy)
when stratified by treatment location (femoral, popliteal, or
tibial) for either women or men (P .05, ns) on univariate
analysis.
DISCUSSION
Recent data suggests that there are between 5 to 7
million persons in the United States alone with lower
Fig 2. Secondary patency rate for all interventions did not differ
significantly by gender. Women had 12- and 24-month secondary
patency rates of 54% 3% and 40% 4%, respectively, while rates
for men were 76%  3% and 67%  4%, respectively.extremity occlusive disease.23-24 Women have generally
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process than men, and to some extent this may be true for
young women before or early into menopause. While the
reasons for this are not well understood, the mechanism
may be related to an atheroprotective environment created
by hormonal and metabolic factors that exist in premeno-
pausal women. However, the incidence of lower extremity
disease in women increases significantly after menopause
and becomes at least equal to men in their sixth and seventh
decades, reaching rates as high as 30% in octogenari-
ans.25-26 Several recent community-based surveys have
even reported higher rates of lower extremity arterial dis-
ease in women compared with men.27-28 Furthermore,
several large studies have demonstrated the fact that in-
creasing proportions of patients treated for lower extremity
occlusive disease are women. In a large study of 5880
surgical reconstructions, Roddy et al found that the per-
centage of female patients treated at their institution in-
crease from 15% to 37% over a 30-year period.17 Similarly,
Hultgren et al found that the proportion of female patients
grew from 34% to 48% between 1970 and 1994 in a large
trial from Sweden.26 During the 5-year period of our study,
interventions on women comprised nearly half the total
number with 447 procedures.
Regardless of the true prevalence rate, multiple studies
have shown that when women with lower extremity disease
seek medical attention they have more advanced disease
than men. In Eugster et al, women were significantly older
(74 years vs 68 years, P  .001) and more likely to present
with limb-threatening ischemia (81% vs 68%, P  .013).29
Fig 3. Limb-salvage rates (in women with limb-threatening con-
ditions) were 81% 3% and 80% 4% at 12 and 24months. These
rates did not vary significantly for men and women.Multiple studies have confirmed the finding that womenare more likely to present with limb-threatening ischemia
than men, a factor which generally is associated with a
poorer outcome, and more likely to require amputation
upon their initial presentation than men.17,30-32 Similarly,
women in the current study were significantly older than
men (73.2 years vs 70.3 years, P  .001) and were more
likely than men to present with limb-threat (62% vs 47%,
P  .0001). Additionally, women were more likely than
men to have lesions of increased complexity as demon-
strated by the higher proportion of TASC C and D lesions
in women than in men (71.4% vs 61.7%, respectively, P 
.005). The reasons for this are likely multifactorial and may
include social isolation, reduced access to care because of
financial reasons, and confusion of symptoms of arterial
disease with those of osteoporosis or arthritis, which are
also prominent in this patient group.33
Intuitively, the more advanced disease at presentation
displayed by women would seem to translate to poorer
outcomes. From the limited available data pertaining to
endovascular intervention in the iliac circulation, this may
be true. There have been a few single institution studies
that have demonstrated significant differences between
men and women treated with percutaneous iliac interven-
tions, with women having decreased immediate and long-
term patency rates.34 These differences were most evident
in one study of women undergoing external iliac artery
interventions; a fourfold increase in stent failure was ob-
served in women relative to men.35
Despite these findings in iliac interventions, differential
gender outcomes may not exist in the infrainguinal loca-
tion. The majority of data pertaining to open surgical
infrainguinal revascularization suggests that women fare as
well as their male counterparts in terms of patency and
limb-salvage rates.11-13,17-18 The primary outcome differ-
ences between men and women undergoing infrainguinal
bypass appear to be related to wound complications, car-
diovascular events, and mortality, as evidence suggests that
these may be higher in females patients.11-12,19,36-37 As
such, percutaneous infrainguinal therapy may be especially
advantageous in women because of the fact that these types
of perioperative complication rates are lower in catheter-
based interventions than in open surgical bypass.
This publication represents the first study focusing on
women with solely infrainguinal percutaneous interven-
tions. A recent publication by Abando et al compared
outcomes following iliac and infrainguinal interventions in
men and women.37 This study included 352 angioplasty
procedures in 248 patients, including 173 interventions in
women. One hundred and seventy-seven of the procedures
were performed in the infrainguinal location, and when
these were stratified by gender there was no difference in
patency between men and women on multivariate analysis.
Similarly, our current study showed no difference in pri-
mary patency, secondary patency, or limb-salvage rates
between genders, even despite more advanced stages of
disease in women upon presentation. Furthermore, unlike
most reports regarding gender differences following open
surgical infrainguinal revascularization, our study did not
id no
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other perioperative events. Men and women did equally
well and had acceptable complication rates following per-
Fig 4. Univariate log-rank analysis revealed several fa
undergoing percutaneous lower extremity intervention.
(B) TASC C & D lesion severity, and (C) diabetes.
Fig 5. Even within high-risk subgroups, patency rates d
ous infrainguinal revascularization.cutaneous intervention.The reintervention rate is an important factor which
may help explain the equivalent outcome across genders
despite the increased likelihood of women to present with
associated with reduced primary patency in women
e included (A) limb-threat as the presenting symptom,
t vary between men and women undergoing percutane-ctors
Theslimb-threat and more severe TASC classification. Women
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same limb following the primary intervention than men
(17.0% vs 12.3%, P  .03). This suggests that reinterven-
tion may be at least partially responsible for the sustained
secondary patency and limb-salvage rates in women com-
pared with men, although it would not impact the primary
patency rate demonstrated here.
Because of the large sample size in this retrospective
study, it was relatively well-powered for detecting a clini-
cally significant difference in patency outcomes between
men and women. On post-hoc power analysis, we found
that the power of this study for the overall Kaplan-Meier
curves for primary patency by gender at the 95% confidence
level was 0.865. Because of the large number of interven-
tions reported, the limit of detection for primary and sec-
ondary patency was well below the observed differences
between genders at 12- and 24-month time points.
CONCLUSION
Percutaneous infrainguinal revascularization has
evolved as an alternative to open surgical bypass with
secondary patency rates of nearly 80% at 1 year. Although
women tend to present with more severe infrainguinal
occlusive disease than men, they appear to have equivalent
patency and limb-salvage rates as men following percutane-
ous intervention. Furthermore, percutaneous intervention
in women may be associated with fewer adverse periopera-
tive events and wound complications than seen with open
surgical bypass. Percutaneous lower extremity intervention
can be considered a safe and effective first line modality in
women with lower extremity occlusive disease.
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Dr Tej Singh (Sunnyvale, Calif). Good morning. President
Ballard, officers, members and guests of the Western Vascular
Society, I wanted to thank you for the opportunity to discuss Dr.
DeRubertis’ well-written and concise manuscript regarding endo-
vascular outcomes for infrainguinal occlusive disease in women
compared with men.
There is no doubt that the content of the study and the topic
in general causes significant discussion and distress at times in our
vascular surgical community. At every hospital in America, endo-
vascular infrainguinal interventions with new technologies are
happening at a rapidly growing rate, even though the indications,
long-term follow-up and consistent results are still not clear. We all
recognize that rapid growth in these procedures does have some
important clinical advantages in appropriately selected patients.
Selection and patient referral patterns may dictate care in many
centers unfortunately.
Dr DeRubertis and his vascular surgery group have described
in this paper their excellent results and clinical follow-up of a large
number of interventional procedures for lower extremity occlusive
disease in both sexes. As he described in his presentation, women
have equivalent outcomes compared with men even though they
may have more advanced disease, increased task severity, and
unknown hormonal effects. This is promising when we all recog-
nize that some women may have poor surgical options and also
tend to have smaller diameter distal targets making surgical options
difficult technically and with known complications. While it is
promising that women and men have equivalent outcomes based
on the study and without necessary randomized trials, I would
caution the reader and the listener from going out and purchasing
arthrectomy and crossing devices for all patients with chronic limb
ischemia. The primary patency of 40%, secondary patency and 60%,
and limb salvage of 80% at 3 years has been reported in other
experienced centers but may not reflect the results in all clinical
practices which I believe may unfortunately be less.
To stimulate discussion, I have three very important questions
for you.
(1) Approximately 22% of the women in the study had chronic
renal failure or were on dialysis. Can you share any thoughts on
this subgroup of patients and how their results compared with
the rest of the study group? And compared with men with
renal disease? In my experience, these vessels are smaller,
calcified especially in women and tend to fair worse both at
surgery and with endovascular treatment.
(2) For planning purposes, did you use CT angiograms or MRAs(3) Do you have any data describing the balloon and stent diam-
eters used in women compared with men correlating that with
body size and weight? I think it would be interesting to see if
women required smaller or similar size endovascular interven-
tions and still had comparable results.
(4) With the increasing use and understanding of crossing devices,
the surgeons in this study did not use them even though most
of the vessels intervened were the SFA. Why? Were there any
characteristics or selection of these patients that limited the use
of crossing devices? If yes, what were they?
(5) Could you provide us some data in how you handle your
endovascular failures? Do you always reintervene? Do you go
straight to surgery? What are your results with failures?
Finally, and probably the most important question, we must
now start thinking beyond just doing these procedures technically
and reporting our results. Can you speculate how to design the
next important studies and what are the important aspects of those
studies for vascular specialists to help treat our patients?
I thank you for the opportunity to discuss your very well written
paper and eagerly look forward to your responses. Thank you.
DrDeRubertis.Dr. Singh, thank you for your discussion and
your very insightful comments.
First, I would like to a comment on the question of whether
our results are generalizable to the entire population. As vascular
surgeons continue to become increasingly familiar with different
devices and gain advanced endovascular expertise, I think these
results will be obtainable across the board in both community and
academic centers. I think the prerequisite, however, is a true
commitment to undertaking these types of procedures, including
the more complex ones. Part of this commitment involves securing
access to the types of imaging systems required and becoming
familiar with the breadth of devices required for the more difficult
cases.
In response to your question regarding patients with chronic
renal insufficiency, in this series approximately 30% of patients had
an elevated creatinine consistent with chronic renal disease. When
looking at all interventions, the overall rate of worsening renal
dysfunction was just over 2%, and this was equivalent between men
and women. In patients with a baseline creatinine less than 3, the
rate of worsening renal dysfunction was around 13% and the need
for hemodialysis was 0.3%. In patients with a creatinine greater
than 3, these rates were about 40% and 25%, respectively, and only
two of the four patients who required dialysis went on to become
chronically dialysis dependent. Both of these patients had baseline
creatinine of greater than 4 and were therefore already moving
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were intervened upon for limb-threat and had no available conduit.
In terms of the outcomes between men and women, there was
no overall difference between genders in terms of patency and limb
salvage, nor were there any differences between men and women
when stratified by baseline preoperative creatinine level. Further-
more, while other studies have demonstrated differential outcomes
in patients with end-stage renal disease on hemodialysis, we did not
observe such a difference. So to summarize our experience with
patients with chronic renal insufficiency, we believe percutaneous
interventions can be done safely provided the baseline creatinine is
under the 2.5 to 3 range and provided one is conscious of the
contrast usage. The vast majority of interventions can be per-
formed using small volumes of 50% contrast by performing selec-
tive runs on appropriate imaging equipment and avoiding unnec-
essary contrast exposure.
In terms of vessel diameters between men and women, we did
not see a difference in balloon and stent sizes between genders. In
the SFA, the average diameter stent was 5.9 for women and 6.1 for
men, which was statistically equivalent. The differences in stent
sizes were based on location, SFA vs popliteal/tibial.
When determining the point at which your endovascular
approach has failed and the time to perform a surgical bypass has
come, some of the issues to keep in mind include the patient’s
conduit, their overall medical condition or surgical risk, and theautologous conduit, one might try a percutaneous intervention
one time and when that fails 6 or 8 months later that patient may
well want the most durable solution to his problem and may elect
at that time for a surgical bypass. On the other hand, in a 90-year-
old patient with recent MI who presents with a nonhealing toe
ulcer, two or three percutaneous interventions, if necessary, may be
appropriate in order to maintain patency long enough to allow the
patient to heal his ulcer and avoid a major operation. I think it
largely depends on what the goals of treatment are. While we hold
no set limits as far as how many interventions one can undergo, we
believe it is of utmost importance to remain conscious of your
surgical bypass targets and avoid any maneuvers that risk injury to
these vessels.
In terms of the next important studies, one relates to the issue
of multiple interventions. We have not yet looked at any cost
analysis aspect of these interventions. I suspect that endovascular
therapy may well be a reasonably sound approach from a financial
standpoint for that first intervention compared with a bypass,
especially considering the economic costs of perioperative compli-
cations associated with each approach. However, as multiple inter-
ventions are performed this cost adds up and may ultimately prove
to be very expensive. Like most available studies on these emerging
technologies, ours is a retrospective analysis of a prospective data-
base and this methodology brings with it certain biases. All of these
modalities need to be further assessed in a prospective randomizedgoals of treatment. In a 50-year-old claudicant who has adequate fashion in the future.
